Persistent chorea in DYT6, due to anticholinergic therapy

E. Antelmi; R. Erro; A. Pisani; N. Mencacci; K. P. Bhatia

doi:10.1016/j.parkreldis.2015.07.024

Persistent chorea in DYT6, due to anticholinergic therapy

E. Antelmi^*, R. Erro, A. Pisani, N. Mencacci, K. P. Bhatia

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English (US)
Article number	2722
Pages (from-to)	1282-1283
Number of pages	2
Journal	Parkinsonism and Related Disorders
Volume	21
Issue number	10
DOIs	https://doi.org/10.1016/j.parkreldis.2015.07.024
State	Published - Oct 1 2015

Funding

K.P.B. has received honoraria/financial support to speak/attend meetings from GSK, Boehringer-Ingelheim, Ipsen, Merz, Sun Pharma, Allergan, Teva Lundbeck and Orion pharmaceutical companies. K.P.B. holds grants from MRC Welcome Strategic grant (Ref. no.: WT089698) and PD UK (Ref. no.: G-1009). EA and RE have been partially supported by the COST (COST Action BM1101; Short Term Scientific Mission).

ASJC Scopus subject areas

Geriatrics and Gerontology
Clinical Neurology
Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.parkreldis.2015.07.024

Cite this

@article{dd86f4dd3af14ef1a862591724db6e8e,

title = "Persistent chorea in DYT6, due to anticholinergic therapy",

author = "E. Antelmi and R. Erro and A. Pisani and N. Mencacci and Bhatia, {K. P.}",

note = "Funding Information: K.P.B. has received honoraria/financial support to speak/attend meetings from GSK, Boehringer-Ingelheim, Ipsen, Merz, Sun Pharma, Allergan, Teva Lundbeck and Orion pharmaceutical companies. K.P.B. holds grants from MRC Welcome Strategic grant (Ref. no.: WT089698) and PD UK (Ref. no.: G-1009). EA and RE have been partially supported by the COST (COST Action BM1101; Short Term Scientific Mission). Copyright: Copyright 2016 Elsevier B.V., All rights reserved.",

year = "2015",

month = oct,

day = "1",

doi = "10.1016/j.parkreldis.2015.07.024",

language = "English (US)",

volume = "21",

pages = "1282--1283",

journal = "Parkinsonism and Related Disorders",

issn = "1353-8020",

publisher = "Elsevier Ltd",

number = "10",

}

TY - JOUR

T1 - Persistent chorea in DYT6, due to anticholinergic therapy

AU - Antelmi, E.

AU - Erro, R.

AU - Pisani, A.

AU - Mencacci, N.

AU - Bhatia, K. P.

N1 - Funding Information: K.P.B. has received honoraria/financial support to speak/attend meetings from GSK, Boehringer-Ingelheim, Ipsen, Merz, Sun Pharma, Allergan, Teva Lundbeck and Orion pharmaceutical companies. K.P.B. holds grants from MRC Welcome Strategic grant (Ref. no.: WT089698) and PD UK (Ref. no.: G-1009). EA and RE have been partially supported by the COST (COST Action BM1101; Short Term Scientific Mission). Copyright: Copyright 2016 Elsevier B.V., All rights reserved.

PY - 2015/10/1

Y1 - 2015/10/1

UR - http://www.scopus.com/inward/record.url?scp=84942198720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942198720&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2015.07.024

DO - 10.1016/j.parkreldis.2015.07.024

M3 - Letter

C2 - 26275586

AN - SCOPUS:84942198720

SN - 1353-8020

VL - 21

SP - 1282

EP - 1283

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

IS - 10

M1 - 2722

ER -

Persistent chorea in DYT6, due to anticholinergic therapy

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this